Emerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin

Repurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer

Xaluritamig (AMG 509): Promising Updates on a STEAP1-Targeted Therapy for Advanced Prostate Cancer